Virtual Library
Start Your Search
H. Sakai
Author of
-
+
Best abstracts selected from submissions 3 (ID 3)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/08/2018, 16:20 - 17:00, Crystal Ballroom 1
-
+
OA06 - Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: (ID 140)
16:20 - 17:00 | Author(s): H. Sakai
- Abstract
Background:
The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in ~3% and 0.4
-
+
Best abstracts selected from submissions 6 (ID 7)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/09/2018, 16:20 - 17:00, Crystal Ballroom 3
-
+
OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227 (ID 166)
16:20 - 17:00 | Author(s): H. Sakai
- Abstract
Background:
CheckMate 227 (NCT02477826), a randomized, open-label, multipart, phase 3 study, demonstrated significant progression-free survival (PFS) benefit with first-line nivolumab + ipilimumab versus histology-based, platinum-doublet chemotherapy (PT-DC) in patients with advanced non-small cell lung cancer (NSCLC) and high tumor mutational burden (TMB; ?10 mutations/megabase [mut/Mb]). Safety was manageable and consistent with prior reports for nivolumab + low-dose ipilimumab. Here we report efficacy and safety of nivolumab + ipilimumab versus PT-DC in the Asian subpopulation from CheckMate 227.
Method:
Patients with chemotherapy-na
